USPTO serial 79337831
ONTELRIQ
Reviewed by CopyMark Law Group
Status 402
- Filing date
- Status date
- Registration date
- —
- Examiner
- AGREDA, SAMANTHA LEIGH
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ONTELRIQ?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ben Natter
Ben Natter Haug Partners, LLP745 Fifth AvenueNew York, NY 10151UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for use in the prevention and the treatment of cancer, orphan diseases, immune disorders, liver diseases, biliary diseases, metabolic diseases, inflammatory diseases, urological diseases, disorders and diseases of the reproductive system, puberty diseases or disorders, gynecological disorders, fertility, acromegalia and tumors, hormonal disorders, endocrine disorders, connective tissue disease, blood diseases, gastrointestinal diseases and disorders, hemophilia, gastrointestinal bleeding disorders, neurological diseases, muscle disorders, bone disorders, skeletal disorders, neuromuscular disorders, cervical dystonia, cerebral palsy, spasticity, blepharospam, migraine, bladder pain syndrome, pain, glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; Pharmaceutical preparations containing notably botulinum toxin, botulinum toxin-haemagglutin complex, botulinum toxin fragments and other botulinum toxin derivatives for skin care and the treatment of neurological disorders; pharmaceutical preparations containing botulinum toxin with specified components of the toxin haemagglutin complex for skin care and the treatment of neurological disorders | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Nov 21, 2023 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Nov 20, 2023 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Oct 31, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 3, 2023 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 26, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 26, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 13, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 13, 2023 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 6, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 6, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Sep 6, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 22, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 19, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 19, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 19, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 27, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Jan 27, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jan 27, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 10, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 9, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 1, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 12, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 8, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 7, 2022 | SDRC | SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB | — |